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Background  and  objective:  Although  positive  screening  for and  treatment  of  obstructive  sleep  apnea  (OSA)
have been  recommended  for patients  with cardiovascular  problems,  patient  adherence  to  nasal  con-
tinuous  positive  airway  pressure  (CPAP)  therapy  primarily  for a  cardiovascular  concern  is  unknown.
Therefore,  this  study  aimed  to determine  the  adherence  to  CPAP  therapy  by  hypertensive  patients  with
OSA  after  a screening  test  performed  regardless  of  OSA-related  symptoms.
Subjects  and  methods:  CPAP  therapy  was  administered  to  194  of  the  1365  hypertensive  patients  who
underwent  the screening.  The  monthly  dropout  from  CPAP  therapy  and  the  adequate  use  level  (4 h every
night,  70%  days  in a month)  were  assessed  using  the  Kaplan–Meier  analysis  over  a 3-year  follow-up
period.
Results:  Of  the  patients,  106  (55%)  refused  or abandoned  the  therapy  by  the  end  of the  follow-up  period
(adherence,  45%).  An adequate  use level  was  maintained  by 76 patients  (39%).  Most  of  the  patients’
background  characteristics,  including  age,  sex, Epworth  sleepiness  scale  scores,  and parameters  obtained
on polysomnography,  were  not  related  to adherence  or adequate  use  level.  The  good-compliance  level  on
the ﬁrst  visit  after  CPAP  therapy  introduction  was  most  strongly  related  to adherence  (95%  CI, 0.05–0.32;
p  <  0.001)  and  adequate  use level  (95%  CI, 0.06–0.33;  p  < 0.05).  Fourth  quartile  of  apnea  hypopnea  index
value  (greater  than 67/h)  was  also related  to adherence  (95%  CI, 0.21–0.98;  p  < 0.02)  and  adequate  use
level  (95%  CI,  0.19–0.88;  p <  0.05).
Conclusions:  The  adherence  and  use  level  in  this  population  may  not  be  satisfactory  but  are comparable
with  those  in previous  sleep  center  reports  treating  symptomatic  OSA  patients.  Thus,  the  present  results
would  encourage  hypertensive  patients  to  undergo  positive  screening  for  OSA,  regardless  of  OSA-related
symptoms.  However,  an outcomes  study  with  the same  cohort  is needed.
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Obstructive sleep apnea (OSA) is characterized by recurrent col-
apse of the pharyngeal airway during sleep, resulting in episodes
f oxygen desaturation and arousal. Experimental data suggest
hat OSA predisposes patients to increased rates of cardiovascular
isease through mechanisms such as increased sympathetic acti-
ation, endothelial dysfunction, insulin resistance, inﬂammation,
nd oxidative stress [1]. An association between OSA and cardio-
ascular problems [1–3] has most convincingly been demonstrated
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in hypertensive patients with OSA [1], and several observational
studies showed a beneﬁcial effect of continuous positive airway
pressure (CPAP) therapy on cardiovascular outcomes [4–6]. On  the
basis of these reports, intervention by CPAP therapy for hyperten-
sive patients with moderate-to-severe OSA is recommended in the
guidelines of the Japanese Society of Hypertension [7] and Japanese
Circulation Society [8].
In our previous study [9], we  developed a screening method
using portable apnea-detecting devices to effectively detect severe
sleep apnea cases among outpatients with hypertension or other
cardiovascular problems. We  performed the screening procedure
in conjunction with pulse wave velocity measurements, regardless
of the presence of OSA symptoms. Therefore, we were able to detect
many severe OSA patients who did not exhibit excessive daytime
sleepiness or other OSA-related subjective symptoms. On the basis
of existing guidelines and the Japanese health insurance policy, we
vier Ltd. All rights reserved.
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ecommended CPAP therapy to patients with an apnea hypopnea
ndex (AHI) ≥ 20. However, we encountered CPAP therapy nonad-
erence by many patients after treatment introduction. Therefore,
e considered it helpful to obtain long-term data on CPAP therapy
dherence of our patients to provide a sample measure for hyper-
ensive OSA patients without speciﬁc symptoms. Should patient
dherence be too low, an alternative screening workﬂow would
e necessary to detect patients who could maintain better CPAP
herapy adherence.
Previous reports [10–22] have indicated various adherence lev-
ls, ranging from 28% to 89%, without showing any consistent
ssociation between CPAP therapy adherence and patient back-
round factors, including age, sex, OSA severity, and measurements
uring sleep studies. In previous reports, the observation periods
or CPAP therapy adherence varied from a few weeks to several
onths. Although the beneﬁcial effect of CPAP therapy on cardio-
ascular outcome is known [23], the relationship between therapy
uration and outcome has not yet been established. The relation-
hip between daily mask-on time and outcome is also unclear.
ome studies [4,11,24] suggest that even low levels of application
rovide some beneﬁt to clinical outcome. In this context, knowl-
dge regarding the time course before CPAP therapy dropout and
hanges in mask-on time could be important information when
onsidering CPAP therapy for cardiovascular event prevention.
Thus, in the present study, we evaluated the long-term adher-
nce of OSA patients to CPAP therapy after our screening method
nd further assessed the data on treatment dropout and ade-
uate treatment use in a survival curve analysis. We  also evaluated
he relationships between these measures and the patients’ back-
rounds.
ethods
We  conducted a retrospective cohort study in a single institute.
he study design was approved by the ethics committee of the
eikyo University School of Medicine (approval No. 09-059; May
7, 2010).
creening session and polysomnography
The precise method for sleep apnea screening using pulse
ave velocity (PWV) measurement sessions followed by overnight
olysomnography (PSG) has been described previously [9]. In
ccordance with the original method, we used only 1 portable
ecording device (FM-500; Fukuda Denshi, Tokyo, Japan) through-
ut the session. Later, we used 3 portable devices to improve apnea
etection. The features of these devices and the apnea-related
easurements obtained during the screening sessions have been
eported previously [25]. The sleep apnea screening test was usu-
lly prescribed to ordinal hypertensive patients and performed
uring regular hospital visits. No patients with non-cardiovascular
roblems such as respiratory or gastrointestinal diseases were
ncluded in this study. Patients who underwent screening between
anuary 2005 and December 2010 were included in the present
tudy. We  recommended PSG to the patients having a respiratory
isturbance index 22/h or more in the screening session according
o the previous report [9].
PAP treatment
After the ﬁrst overnight PSG, CPAP titration was recommended
o all the patients and performed with attendant manual titra-
ion under PSG monitoring. CPAP therapy with ﬁxed pressure was
rescribed to the patients. Meanwhile, auto CPAP therapy was  pre-
cribed to patients who refused to undergo CPAP titration.diology 63 (2014) 281–285
Before treatment initiation, all of the subjects attended an edu-
cational session on the use of CPAP therapy, including face-to-face
information provided by the treating physicians. Mask interface
was selected according to the patients’ preference. All the patients
received a CPAP unit (REMstar Pro or REMstar Auto M;  Phillips,
Murrayville, PA, USA) that recorded daily mask-on time (i.e. the
time the CPAP circuit was pressurized at the prescribed level) on
a data card. The data cards were collected approximately once per
month. The ﬁrst day of CPAP therapy use was  deﬁned as the ﬁrst
day during which any pressurized mask-on time was recorded by
the CPAP electronic card monitor after delivery of the CPAP device
to the patient.
Outcome and statistical analysis
Monthly CPAP therapy use and sufﬁcient mask-on time during
the follow-up period were the primary outcomes of our analy-
ses. We deﬁned dropout event as a patient’s ﬁrst month without
CPAP therapy use (i.e. total mask-on time in a month was 0). The
event included the refusal to undergo CPAP therapy during the
educational session. CPAP therapy adherence was  calculated as
the fraction in the cohort of patients who did not experience a
dropout event at a given point. We  also deﬁned poor-compliance
event as the point from which adequate mask-on time was  no
longer observed. Adequate mask-on time was  deﬁned as a mini-
mum of 70% of days with at least 4 h of mask-on time in a
month. Dropout events were counted in the poor-compliance
events. Adequate use level was calculated as the fraction in the
cohort of patients who had no poor-compliance events at a given
point.
A statistical software package (JMP v. 9.04, SAS Institute, Cary,
NC, USA) was used for data processing and statistical analysis.
Continuous variables were expressed as mean ± SD values; and
qualitative variables, as percentages. A t test or an analysis of
variance was used for continuous variables; and a 2 test, for
qualitative variables. Event rates were calculated according to the
Kaplan–Meier method, and adherence and adequate use level were
compared using the log-rank test. The log-rank test for trend was
used to assess the probability of a trend in events across the groups.
Assumption of proportional hazards was assessed graphically using
a log-minus-log survival graph. In the ﬁrst phase, a univariate anal-
ysis based on a proportional hazards model was performed to
determine any relationship between the adherence-related events
and the following independent pretreatment variables: age, sex,
BMI, Epworth sleepiness scale (ESS) score, current or previous
smoking habit, systolic and diastolic blood pressures before CPAP
therapy, number of antihypertensive medications, resistant hyper-
tension [26], comorbidity (dyslipidemia, diabetes mellitus, and
ischemic heart disease), AHI, ODI (oxygen desaturation index),
total sleep time, percentage sum of sleep stages III and IV, per-
centage of REM sleep, and ﬁnal mode of CPAP therapy (auto or
ﬁxed). Good compliance (absence of a poor-compliance event) on
the ﬁrst visit after CPAP therapy introduction was analyzed as an
independent factor. AHI was categorized into quartiles with cut
points 24.5, 40.7, and 67.1 to allow for the demonstration of a pos-
sibly nonlinear association. Participants in the lowest quartile of
AHI served as the reference group. Variables found to have possi-
ble relations (i.e. p < 0.10) were included in a multivariate analysis
using a time-dependent Cox model; however, the assumption of
proportional hazards was  not veriﬁed. The interaction betweenincluded in the Cox analysis. The results of the Cox multivariate
analysis were expressed as the risk ratio with a 95% conﬁdence
interval. A 2-tailed p < 0.05 was considered to be statistically
signiﬁcant.
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Table 1
Patient background at different stages.
Screening Full PSG Inclusion p
n 1365 250 194
Male:female 894:471 174:76 149:45 NS
Age  (y) 66.4 ± 11.3 64.6 ± 11.3 64.8 ± 10.8 NS
ESS  score 5.5 ± 3.7 7.2 ± 4.5 7.0 ± 4.2 NS
BMI  (kg/m2) 24.5 ± 4.4 26.9 ± 4.5 26.4 ± 4.2 NS
BP  (mm  Hg)
Systolic 129.9 ± 17.9 130.7 ± 18.4 132.1 ± 15.0 NS
Diastolic 76.8 ± 11.7 78.9 ± 12.2 80.9 ± 11.2 NS
AHI  45.9 ± 29.2 53.8 ± 27.8
AHI ≥ 20 203 194
AHI ≥ 30 177 158
PSG, polysomnography; ESS, Epworth sleepiness scale; BMI, body mass.
Table 2
Data on comorbidities, antihypertensive patients, and parameters obtained from
the  sleep study in the follow-up cohort.
Inclusion cases No. of patients (n = 194)
Comorbidity (n)
Diabetes mellitus 25 (13%)
Dyslipidemia 28 (14%)
Ischemic heart disease 41(21%)
Smoking habit 134 (69%)
No. of antihypertensive patients 2.0 ± 1.3
Resistant hypertension 26 (13%)
Sleep study
Total sleep time (min) 323.7 ± 87.1
T
R
i
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esults
During the enrollment period, 1365 patients underwent the
creening test. We  excluded the data from 122 nonhyperten-
ive patients. Of the 1243 remaining patients, 250 underwent
ull PSG afterward. The AHI was >20 in 203 of these patients.
ne patient had predominant central apnea, and 8 patients were
ransferred to another clinic; the data from these patients were
ot considered in later analyses. Thus, a total of 194 patients
ere enrolled for the follow-up stage. The baseline characteris-
ics of the patients in these 3 stages are presented in Table 1.
he mean Epworth sleepiness scale score was <7, and most of
he patients were free from excessive daytime sleepiness. The
atient characteristics in the 3 diagnostic stages were not signif-
cantly different, except for the AHI. According to the American
cademy of Sleep Medicine classiﬁcation system, 156 patients
80%) in the follow-up cohort had severe OSA. The comorbidities,
umber of antihypertensive medications, and PSG-related param-
ters in the follow-up stage are summarized in Table 2. All but
1 patients were taking at least 1 antihypertensive drug. Lifestyle
odiﬁcation alone was  recommended to these 21 patients at
he beginning of the observation; an antihypertensive drug was
ater administered to 9 of these patients during the observation
eriod. Sixty-four patients had more than 3 medications, of whom
6 had a systolic blood pressure > 140 mmHg  or a diastolic blood
ressure > 90 mmHg  and hence were considered to have resistant
ypertension [26]. All the patients selected a nasal mask for the
PAP therapy interface. The comorbidities in the enrolled patients
re summarized in Table 3. No patient had heart failure, and adap-
ive servo-ventilation or home oxygen therapy was  not used in
hese patients.
ODI 3% 38.9 ± 21.6
Sleep stage III + IV (%) 2.8 ± 6.6
Sleep stage REM (%) 13.8 ± 7.2
ODI, oxygen desaturation index; REM, random eye movement.
able  3
esults of univariate and multivariate analysis correlating drop off and poor compliance events. BMI: body mass index; ESS: Epworth sleepiness scale; AHI: apnea hypopnea
ndex; ODI: oxygen desaturation index.
Univariate analysis Dropout Poor-compliance
p RR 95% CI p RR 95% CI
Sex (male) 0.98 1.00 0.70–1.45 0.97 0.94 0.60–1.54
Age  0.40 0.98 0.99–1.02 0.70 0.99 0.97–1.01
BMI  0.87 1.00 0.97–1.04 0.67 1.01 0.96–1.06
ESS  0.80 1.01 0.94–1.07 0.84 1.01 0.95–1.07
Smoking 0.57 0.57 0.79–1.54 0.94 1.01 0.66–1.59
Dyslipidemia 0.21 0.71 0.43–1.12 0.42 0.55 0.22–1.07
Diabetes mellitus 0.43 0.84 0.51– 1.28 0.23 0.67 0.31–1.26
Ischemic heart disease 0.30 1.0 1.00–1.00 0.29 0.29 0.76–2.26
Pretreatment blood pressure
Systolic 0.11 0.87 0.98–1.01 0.19 0.97 0.96–1.01
Diastolic 0.64 1.00 0.99–1.01 0.54 1.01 0.99–1.03
Number of antihypertensives 0.36 0.98 0.96–1.01 0.18 0.89 0.75–1.12
Resistant hypertension 0.39 0.81 0.48–1.29 0.35 0.56 0.23–1.13
AHI  (Quartile) 0.06 (p for trend) 0.07 (p for trend)
ODI  (3%) 0.08 0.97 0.98–1.00 0.09 0.99 0.97–1.00
Total  sleep time 0.29 0.99 0.99–1.00 0.62 0.99 0.99–1.00
Sleep  stage
REM 0.48 0.98 0.97–1.33 0.41 0.99 0.96–1.02
Stage  III + IV 0.19 1.01 0.96–1.01 0.34 1.01 0.98–1.04
Arousal index 0.21 0.99 0.98–1.00 0.33 0.99 0.98–1.01
CPAP  mode (ﬁxed) 0.22 1.48 0.97–2.88 0.34 0.65 0.36–1.15
Good  compliance on the ﬁrst visit <0.01 0.44 0.30–0.62 <0.01 0.07 0.02–0.33
Multivariate analysis Drop off Poor compliance
p RR 95% CI p RR 95% CI
Good compliance on ﬁrst visit <0.01 0.14 0.05–0.32 <0.01 0.18 0.07–0.36
AHI  0.16 (p for trend) 0.03 (p for trend)
Quartile 1 (20.0–32.6) – 1.00 Reference – 1.00 Reference
Quartile 2 (32.7–47.4) 0.09 0.54 0.30–1.09 0.45 0.15 0.82–1.09
Quartile 3 (47.5–66.5) 0.19 0.59 0.26–1.29 0.45 0.74 0.33–1.60
Quartile 4 (66.5–139.7) 0.03 0.28 0.08–0.90 0.03 0.24 0.07–0.81
ODI  (3%) 0.43 1.00 0.97–1.02 0.86 1.00 0.98–1.02
 < 0.1 for univariate analysis and p < 0.05 for multivariate analysis.
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The mean follow-up duration was 37.9 months (range, 0–96
onths). By the end of the study, 106 (55%) dropout events and 118
61%) poor-compliance events occurred. The monthly adherence
nd adequate use level, as calculated on the basis of the dropout
vents, are illustrated in Fig. 1. Thirty-three patients (17%) refused
o undergo CPAP therapy after the educational session. Auto CPAP
herapy was prescribed to 112 patients (58%), whereas CPAP ther-
py with a ﬁxed pressure level was prescribed to the remaining 49
atients (25%) after a titration PSG study. Sixty-four (33%) dropout
vents and 85 (44%) poor-compliance events, including those in
he patients who refused treatment, were observed on the ﬁrst
ollow-up visit after the educational session. During this time, mod-
ﬁcations in the CPAP therapy were made in 51 patients (26%),
hich included changes in CPAP mode (from auto to ﬁxed pres-
ure) in 41 patients and changes in pressure levels in the other 10
atients. In all the patients, objective compliance could be assessed,
ielding a mean of 4.9 ± 2.1 h/d.
Table 3 (top) shows the results of the univariate analysis corre-
ating 2 events and the independent variables tested in this study.
he variable “good compliance on the ﬁrst visit” had strong effects
n both events. The additional variables ﬁnally included in the mul-
ivariate analysis for both events were AHI (quartile) and ODI. The
esults of the multivariate analysis using a time-dependent Cox
odel are shown in Table 3 (bottom). The variable “good com-
liance on the ﬁrst visit” was a strong independent predictor for
on-occurrence of both events. AHI quartile 4 to quartile 1 had also
igniﬁcant relation to both events.
iscussion
The primary ﬁnding of this study was that approximately half of
he hypertensive OSA patients who had no OSA-related symptoms
ontinued with the CPAP therapy for 3 years, which is comparable
o the long-term adherence to CPAP therapy in previous reports
rom sleep centers or clinics [10–22]. However, our data are unique
ecause the diagnoses in all the patients were made regardless of
SA-speciﬁc symptoms and CPAP therapy was introduced follow-
ng current guidelines [7,8]. We  consider our results adequate to
ncourage hypertensive patients to undergo screening and treat-
ent with CPAP therapy, as we can expect approximately half of
he patients to succeed with CPAP therapy regardless of symptoms,
ge, or other patient background characteristics. The prevalence
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ig. 1. Monthly continuous positive airway pressure (CPAP) therapy adherence and
dequate use level during the observation period. The values were calculated as the
umber of patients free from dropout and poor-compliance events, respectively.diology 63 (2014) 281–285
of symptomatic OSA in the general population was  reported to
be 2–3% [27], and another report indicated that the prevalence of
asymptomatic OSA in Japanese male is 22.3% [28]. According to
the national government’s social insurance report (e-Stat), the total
number of CPAP therapy users in Japan was estimated to be approx-
imately 200,000 patients in June 2011, which means that between
2 million and 20 million OSA patients in Japan were untreated.
The impact on healthcare would be large if even just half of these
patients were to continue with CPAP therapy.
Furthermore, other information necessary to promote screening
and treatment for OSA patients is the key characteristics of adherent
patients among a cohort similar to that of our study. A num-
ber of studies have attempted to identify contributing factors and
predictors for CPAP adherence. While some studies have found
relationships between sex, age, severity of disease, symptoms of
sleepiness, and socioeconomic status to subsequent adherence to
CPAP therapy, the ﬁndings are inconsistent [29–31]. The charac-
teristics of subjects might contribute to the inconsistent results,
and most of the patients’ characteristics were not related to CPAP
therapy adherence in this study. However, AHI quartile 4, which
is a very severe group with AHI more than 67/h, had better adher-
ence and CPAP usage than the quartile 1. Although respiratory event
≥30 events/h have been recognized as one of the factors affecting
CPAP adherence [31], patients in the cohort had higher thresholds
for better CPAP adherence. Such a high threshold of cut-off level
for good CPAP usage was reported previously [32]. We found that
the relationship between AHI and CPAP adherence was non-linear
in the cohort. Therefore, we  consider that threshold or cut-off level
should be carefully selected in comparison of clinical outcome and
OAS severity in patients in a cohort like this study. The variable
“good compliance on the ﬁrst visit” was  the most powerful predic-
tor for good adherence in our cohort. This ﬁnding is similar to those
observed in OSA cases in sleep centers [22,33–37]. Ease of use and
comfort of the CPAP mask may  be related to many factors, includ-
ing upper airway structure, skull shape, and soft tissue volume of
patients and such factors may  not be evaluated easily before actual
CPAP therapy use. Newer studies suggest that cognitive behavioral
therapy and standard education could increase CPAP use [31]. Such
interventions would improve CPAP adherence regardless of patient
characteristics.
CPAP therapy was considered to be cost-effective and econom-
ically reasonable after several observational studies [4–6,23] and
ranked as a class I recommendation as a therapy for patients with
cardiovascular problems, including hypertension, in a Japanese
guideline [8]. However, the shortest or optimal length and fre-
quency of CPAP use required for achieving the best cardiovascular
outcomes remains unknown. The recommended frequency of CPAP
use for ordinal OSA patients is between 6 and 8 h per night, but
researchers have deﬁned CPAP therapy adherence as a mean of 4 h
a night for 70% of the nights in a month [12]. One of the studies
[4] indicated that CPAP therapy use for more than 1 h might con-
tribute to the all-cause mortality in ordinal OSA patients. However,
we do not know whether that is the case for patients free from OSA-
related symptoms. The precise relationships between frequency
of use and outcome should be elucidated in a cohort such as that
of the present study. Our present data provide a sample of actual
adherence levels and useful information for other outcomes study.
A few limitations of this study should be noted. Given the retro-
spective nature of our study, comorbidity and habits were assessed
by clinical data obtained from review of patients’ charts, and the
association between the analyzed factors and CPAP usage were
observational. No limitation was made for pharmacotherapy to
the patients. Thus, we had not analyzed blood pressure change of
individual patients in our cohort, although we  recognize that the
CPAP effect on blood pressure level is an important issue. A few
reports including meta-analysis showed the modest CPAP effect on
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eﬁnitely needed in future.
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